OraSure Technologies, Inc. (NASDAQ:OSUR) Stock Holdings Boosted by Systematic Financial Management LP

Systematic Financial Management LP lifted its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 14.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,252,112 shares of the medical instruments supplier's stock after purchasing an additional 162,364 shares during the quarter. Systematic Financial Management LP owned about 1.68% of OraSure Technologies worth $5,347,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in OSUR. Millennium Management LLC raised its position in shares of OraSure Technologies by 727.5% during the 2nd quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier's stock worth $8,610,000 after purchasing an additional 1,776,867 shares during the period. Acadian Asset Management LLC raised its position in shares of OraSure Technologies by 38.1% during the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier's stock worth $9,349,000 after purchasing an additional 605,324 shares during the period. American Century Companies Inc. raised its position in shares of OraSure Technologies by 30.1% during the 2nd quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier's stock worth $7,710,000 after purchasing an additional 418,603 shares during the period. Renaissance Technologies LLC raised its position in shares of OraSure Technologies by 20.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier's stock worth $9,749,000 after purchasing an additional 391,100 shares during the period. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of OraSure Technologies during the 2nd quarter worth approximately $1,602,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Price Performance

OSUR stock traded up $0.07 on Friday, reaching $3.91. The company's stock had a trading volume of 773,278 shares, compared to its average volume of 889,858. OraSure Technologies, Inc. has a 52 week low of $3.72 and a 52 week high of $8.45. The company has a market capitalization of $291.65 million, a P/E ratio of 26.07 and a beta of 0.03. The firm has a fifty day moving average of $4.04 and a two-hundred day moving average of $4.26.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $39.92 million during the quarter, compared to analyst estimates of $38.97 million. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The business's revenue for the quarter was down 55.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.27 EPS. As a group, equities analysts expect that OraSure Technologies, Inc. will post -0.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised OraSure Technologies from a "hold" rating to a "buy" rating in a report on Friday, October 4th.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.